NIH team touts experimental Epstein-Barr virus vaccine; Madison Vaccines pairs its prostate cancer jab with Keytruda;

> A nanoparticle-based experimental vaccine, developed by a team from the National Institute of Allergy and Infectious Diseases and its collaborators, was shown to induce antibodies against Epstein-Barr virus in mice and primates. Release

> Madison Vaccines initiated a combination trial of its lead prostate cancer vaccine candidate paired with Merck's ($MRK) checkpoint inhibitor Keytruda. Release

> Emergent BioSolutions ($EBS) received a $44 million contract option for the supply of its Vigiv--which treats complications due to smallpox vaccination--to the national stockpile. Release

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.